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NanoViricides, Inc. is a publicly traded company (stock symbol: NNVC, OTC).   
 
This is not an offering memorandum and should not be construed as such.  
It is provided as a non-confidential document for informational purposes only. 
 
NanoViricides, Inc.(www.nanoviricides.com) is a development stage company that is creating special purpose 
nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically 
attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral 
diseases including H1N1 “swine flu”, H5N1 bird flu, seasonal Influenza, HIV, EKC, Herpes “cold sores” and genital Herpes, 
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.  
 
This document contains forward-looking statements that reflect the current expectation of  NanoViricides, Inc. (the 
"Company) regarding future events. Actual events could differ materially and substantially from those projected herein and 
depend on a number of factors. Certain statements are “forward-looking statements” within the meaning of Section 27A of 
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on 
forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some 
cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, 
performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking 
statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these 
forward-looking statements, even if new information becomes available in the future. Important factors that could cause 
actual results to differ materially from the company's expectations include, but are not limited to, those factors that are 
disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the 
United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict 
or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a 
nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain 
regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our 
product candidates; and market acceptance of our products. 
Disclosure Statement 
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What is a NanoViricide®? 
FIND the enemy... 
Ligands 
Target Virus Particle 
 
“Guided Missile” 
API’s 
Active Pharmaceuticals 
can be Encapsulated in the 
“Belly” of the nanoviricide 
 
Future Drugs -  
Creating Cures? 
ENCAPSULATE enemy... 
“Nanomicelle” 
A folded-up glob that can unfold and 
spread onto the virus particle after 
ligands bind to the virus 
 
“Attack from all around” 
DESTROY the enemy... 
“Nanoviricide” 
The virus thinks it bound to a host cell, 
starts its own unfolding machinery,  
destroying itself in the process 
 
Tricking the Virus 
Innovation... 
Slide 
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A NanoViricide® Attacking a Virus Particle: 
Unique, Novel, Nanotech Design 
A single nanoviricide micelle may be capable of completely engulfing a Virus Particle.   Nanoviricide micelles self-assemble 
from multiple chains.  A single chain micelle shown for convenience. Illustration not to scale.  
Schematic Diagram Not Intended to be Construed as the In Vivo Mechanism 
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Our Current Drug Programs 
Post-Discovery 
EBV 
RSV,  
Chikungunya, 
Rotavirus... 
Hepatitis C 
Ebola, 
Marburg, 
Rift Valley Fever, 
Hemorrhagic 
Viruses 
Rabies 
HIV 
Oral & Genital Herpes 
(“Cold Sores”)  
 
EKC Causing  
Adenovirus 
Pre-clinical Leads 
* FluCide™ one Drug 
for All  
* Eye Drops for All Viral 
Conjunctivitis/Keratitis 
* Skin Cream & Gel for Oral, 
Genital Cold Sores 
* HIVCide™ Potentially 
“Functional Cure” 
* Dengue nanoviricide -
avoid ADE Effect 
Dengue Virus,  
West Nile Virus,  
Yellow Fever Virus,  
Jap. Encephalitis Virus 
Influenzas 
H5N1 Bird Flu 
H7N, H9N, High 
Path Avian 
Influenzas 
 
Epidemic H1N1 
“Swine Flu” 
 
Seasonal Influenzas 
Clinical 
Lead 
HSV 
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>1,000-fold Lung Viral Load Reduction in NanoViricide 
Treated Animals  
Only <2-fold reduction with Oseltamivir in this study 
4.5 Days (108h) Post-Infection 
NV-3 NV-4 NV-5 Oseltamivir Control 
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Sustained Reduction in HIV-1 Viral Load  
Even After Treatment Stopped  
in the SCID-hu Thy/Liv Mouse Model Study #2 
NV-5B Treatment stopped at 20 days,  
yet antiviral effects (viral load, CD4+-CD8+ DP cells, Total T 
cells)  
lasted at least through 48 days 
NV-5B Trtmt 1,200 mg/kg 
HAART Trtmt 4,800 mg/kg 
Day 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 
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NanoViricides: 
Beyond Immunotherapeutics! 
✴ Immunoglobulins, Antibodies : Standard Antiviral Treatments 
✴NanoViricides are Designed to Neutralize the Virus Particle 
Completely and Dismantle it  
✴Nanoviricides Do Not Depend Upon the Immune System to 
encapsulate and dismantle the virus, as antibodies do 
✴Nanoviricides Strategy: Seek, Attach, Encircle and Destroy 
‣ Classic War Strategy! 
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relative to NanoViricides 
FDA Regulatory Environment 
✴Efficacy   - YES 
✴Safety    - YES 
✴Consistency:  CMC - Chemistry, Manufacture, Controls 
‣ Chemistry - Translate from bench Chemistry to Production 
‣ Polymeric Nature Poses Limitations  
• Many Polymers Already in Medicinal Practice 
‣ Controls  
• Similar to Usual Small Chemicals 
• Additional Characterization and Controls 
‣ Batch to Batch Reproducibility 
Regulation... 
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relative to NanoViricides 
FDA Regulatory Environment: cGMP 
✴Capabilities Issues with CMOs 
✴Transfer/Translation Load Issues at NanoViricides 
✴Overall Costs - Initial, Milestone, Recurring 
✴Timeline Goals 
✴Uncertain Regulatory Needs Dictate that  
We Need to Have Control 
Regulation... 
Chose to Do it On Our Own 
 
Building Purchased (3rd Party) 
 
Renovation being Planned and Designed 
Aggressive 9 month Goal 
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FDA Regulatory Environment: Clinical Path 
✴Guidelines for Nanomedicines: 
No New Guidelines Needed; Case-by-Case 
✴Clear Clinical Path for Influenza 
✴High Efficacy should translate into  
Lower Clinical Trials Costs and  
Shorter Timelines 
✴Experienced Consultants 
✴Uncertain Regulatory Environment 
Regulation... 
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Public Company - 
Equity Market Financing 
Financing & 
Investments... 
✴ Took NanoViricides Public -  
‣ Reverse Shell Merger - June 2005 
✴ To date, Raised about $31M 
‣ about $11M cash in hand 
‣ current expense rate ~ 6M/yr 
✴Stock Market Uncertainties 
✴Global Economic Uncertainties 
✴Changes in Investment Models 
✴Changes in Investor Models 
✴ Late Revenue in Pharma Business 
✴ Licensing Deals in First-In-Class  
Nanomedicines 
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Large Market Sizes:  
Strong ROI Opportunity 
Disease/Virus 
$ Billions, 2013 
estimates (1) 
HIV/AIDS $ 21 B     . 
HIV-Cide™ Potentially  
a “Functional Cure”  
Influenzas $ 7 B     . 
Resistance to Current Drugs widespread.  
FluCide™ as a Pan-Influenza Drug 
Eye Drops Antiviral $ 1~5 B (2) . No current non-toxic drugs 
Herpes “Cold Sores” 
Skin Cream & Gel 
$ 2 B     . 
Current therapies have limited 
effectiveness 
Hepatitis C $ 6 B     . Current therapies not very effective 
Dengue, Rabies, other 
NTD’s 
$ 1 B (2) . 
combined           
Rapidly increasing developing world 
markets not properly accounted for 
Ebola/Marburg/VHF 
$ 1 B     . 
combined           
Biodefense; Single customer issues 
Government Grants & Contracts 
(1). Jain Pharma Biotech. March 2009. “Antiviral Therapeutics: Technologies, Companies & Markets”, by Prof. K. K. Jain, MD, FRACS, FFPM. Basel, Switzerland.   
(2). Estimates based on the Jain Report, and a report commissioned by the Company for more detailed  analyses of these special markets. March 2009.  
Financing & 
Investments... 
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NanoViricides: Strong Product PipeLine 
Disease Drug Candidates 
Efficacy - Cell Cultures  
Safety - Animals 
Efficacy - 
Animals 
IND-Enabling Studies 
Phase I, II, III, 
NDA 
  Primary (Commercially Important) Programs  
Influenza, Bird Flu* FluCide™-I 
External Eye Viral Diseases EKC-Cide™-I 
HIV/AIDS HivCide™-I 
Herpes Oral and Genital Identified 
Dengue Identified 
  Neglected Tropical Diseases Programs - Social Responsibility  
Rabies RabiCide™-I 
  Bio-Defense Programs  
Ebola/Marburg TBD 
ADIF™ Technology** ADIF-Base™-I 
*    Includes all highly pathogenic avian influenza (HPAI) viruses capable of causing severe human epidemics, such as H5N1, H7N, H9N.  
**  ADIF: “Accurate-Drug-In-Field” is NanoViricides, Inc. unique technology. The ADIF-Base nanomicelles can be stockpiled. When a novel infection (natural or bioterrorism) occurs, a 
nanoviricide against that virus can be quickly created in the field and used to stop an epidemic from spreading.  
We plan on obtaining non-equity funding for our NTD and Bio-defense programs. The Company believes that these programs benefit our commercially important drug development programs, 
and vice versa.   
The Regulatory Process is complex. A Tox Package needs to be developed for each drug candidate. Then an IND is submitted to the FDA. Human Clinical Trials, Phase I, II, and III, are 
conducted upon IND approval. An NDA is submitted after that. A drug can be marketed only after FDA approval. The Company cannot reliably predict timelines for these events, nor can it 
assure that it will be successful in developing any drugs.  
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The End 
